BioKangtai Reaches Vaccine Technology Transfer Cooperation Intent with Ethiopia

In March 2025, a delegation from the Ethiopian Ministry of Health visited BioMinhai, a wholly-owned subsidiary of BioKangtai. Representatives from BioKangtai and several domestic supply chain enterprises warmly welcomed the delegation.

During the symposium, the Ethiopian delegation highlighted the development of Ethiopia's vaccine production infrastructure and expressed a strong desire to collaborate with advanced Chinese vaccine companies like BioKangtai on extensive vaccine technology transfer.

BioKangtai showcased its robust R&D capabilities and reaffirmed its commitment to international vaccine cooperation, particularly with countries along the "Belt and Road." The company hopes to partner with Ethiopian health authorities to advance vaccine technology transfer, enhancing local vaccine production capabilities and supporting global health security.

This visit marks a significant step in BioKangtai's ongoing efforts to expand its international presence and contribute to the global fight against infectious diseases through strategic partnerships.